Company Overview and News

0
INTERVIEW | After 21 mln tn capacity, SAIL aims to achieve 50 in 15 years with zero sales of semis: Chairman PK Singh

2018-06-05 moneycontrol
PK Singh has an onerous task. As Steel Authority of India Chairman, he steers many of India’s first Prime Minister Jawaharlal Nehru’s Temples of Modern India – the Rourkela, Bhilai, Durgapur, Bokaro and Burnpur steel plants. But in the marketplace, leadership is more an outcome of business acumen than history. It is this understanding that has helped Singh as he attempts to put a little bit of SAIL (back) in everybody’s life.
MODERN 503015

0
Ambedkar Jayanti 2018: 15 facts about the Founding Father of Modern India

2018-04-14 freepressjournal.in
Bhimrao Ramji Ambedkar, fondly known as Babasaheb, was an Indian jurist, economist, politician and social reformer who campaigned against social discrimination of Dalits in the Indian society. He was the principal architect of India’s Constitution and India’s first law minister. Born on April 14, 1891 to Bhimabai Sakpal and Ramji Maloji Sakpal in Madhya Pradesh, he was a multi-faceted personality who fought against the caste system and socio-economic deprivation.
MODERN 503015

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

13h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...